Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug trial aims to protect kidneys in serious lupus complication

NCT ID NCT07201129

Summary

This study is testing whether adding an experimental drug called cenerimod to standard lupus nephritis treatment helps improve kidney function better than standard treatment alone. About 300 adults with active lupus-related kidney inflammation will take either cenerimod or a placebo pill daily for 76 weeks while continuing their regular medications. Researchers will compare kidney test results to see if cenerimod helps reduce protein in urine and maintain kidney filtering ability.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Allied Biomedical Research Institute

    RECRUITING

    Miami, Florida, 33155, United States

  • Northwest Houston Arthritis

    RECRUITING

    Houston, Texas, 77090, United States

  • ProfessionalResearchCenter INC

    RECRUITING

    Miami, Florida, 33172, United States

  • Rheumatology Care Center, PLLC

    RECRUITING

    Bellaire, Texas, 77401, United States

  • San Marcus Research Clinic, Inc.

    RECRUITING

    Miami Lakes, Florida, 33014, United States

  • SouthCoast Research Center

    RECRUITING

    Miami, Florida, 33136, United States

Conditions

Explore the condition pages connected to this study.